Group 1 - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is recognized as a top immunotherapy stock by hedge funds, with RBC Capital maintaining a Hold rating and a price target of $745.00 [1] - Regeneron is expanding its immunology portfolio, with 36 abstracts related to its immunology and inflammation pipeline to be presented at the 2026 AAAAI Annual Meeting [3] - The company reported significant developments, including Phase 3 allergen-specific programs targeting ocular symptoms in adults with cat and birch allergies, and new analyses of Dupixent® across various diseases [4] Group 2 - Guggenheim raised its price target for Regeneron to $975 from $865, maintaining a Buy rating and highlighting key upcoming catalysts such as fianlimab/Libtayo LAG-3 data and an FDA decision for Eylea HD [5] - Regeneron focuses on developing therapies for diseases including cancer, eye disorders, and allergic conditions [6]